PhRMA names Horizon CEO board member
This article was originally published in Scrip
Executive Summary
Timothy P Walbert, chair, president and CEO of Horizon Pharma, has been named a member of the board of directors for the Pharmaceutical Research and Manufacturers of America (PhRMA). PhRMA represents the country's leading biopharmaceutical research and biotechnology companies, and is devoted to advancing public policies in the US and around the world that support innovative medical research. Mr Walbert joined Horizon Pharma in 2008 as president and CEO, and has served as chair of the company's board of directors since 2010. Prior to joining Horizon, Mr Walbert was president, CEO and director of IDM Pharma, a public biopharmaceutical company acquired by Takeda in June 2009.
You may also be interested in...
Six New Molecules By 2030 – J&J’s Neuroscience Strategy
Can neuroscience be precise? Peter Fang, worldwide VP of neuroscience, explains J&J's approach to precision medicine in Alzheimer’s disease, depression and other neurological conditions.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.